Evidence map›Paper›PMID 37843120›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.

Heather R Cross, Kerryl E Greenwood-Quaintance, Maria Souli, Lauren Komarow, Holly S Geres, Toshimitsu Hamasaki, Henry F Chambers, Vance G Fowler, Scott R Evans, Robin Patel and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Heather R CrossDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Kerryl E Greenwood-QuaintanceDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Maria SouliDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Lauren KomarowBiostatistics Center, Department of Biostatistics and Bioinformatics, George Washington University, Rockville, Maryland, USA.
Holly S GeresDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Toshimitsu HamasakiBiostatistics Center, Department of Biostatistics and Bioinformatics, George Washington University, Rockville, Maryland, USA.
Henry F ChambersDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, California, USA.
Vance G FowlerDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Scott R EvansBiostatistics Center, Department of Biostatistics and Bioinformatics, George Washington University, Rockville, Maryland, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Antibacterial Resistance Leadership Group

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681NIH HHS UM1AI104681
6 · The paper itself

Abstract

Developing and implementing the scientific agenda of the Antibacterial Resistance Leadership Group (ARLG) by soliciting input and proposals, transforming concepts into clinical trials, conducting those trials, and translating trial data analyses into actionable information for infectious disease clinical practice is the collective role of the Scientific Leadership Center, Clinical Operations Center, Statistical and Data Management Center, and Laboratory Center of the ARLG. These activities include shepherding concept proposal applications through peer review; identifying, qualifying, training, and overseeing clinical trials sites; recommending, developing, performing, and evaluating laboratory assays in support of clinical trials; and designing and performing data collection and statistical analyses. This article describes key components involved in realizing the ARLG scientific agenda through the activities of the ARLG centers.

Indexed as

Data ManagementLeadershipAnti-Bacterial AgentsData CollectionDrug Resistance, BacterialHumansAnti-Bacterial Agentsantibacterial resistanceclinical trial networkinfectious diseaselaboratory testingstatistics

Identifiers

PMID37843120
PMCPMC10578052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.